- TRICYCLIC DLK INHIBITORS AND USES THEREOF
-
The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
- -
-
Page/Page column 65-66
(2016/09/26)
-
- 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS
-
The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
- -
-
Page/Page column 100; 101
(2014/08/06)
-
- IMIDAZOPYRIDIN-2-ONE DERIVATIVES
-
A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.
- -
-
Page/Page column 65
(2011/04/24)
-
- Discovery of new azaindole-based PI3Kα inhibitors: Apoptotic and antiangiogenic effect on cancer cells
-
Phosphatidylinositol-3-kinase alpha (PI3Kα) is an important target in cancer due to the deregulation of the PI3K/AKT signaling pathway in many tumors. In this study, we designed [3,5-d]-7-azaindole analogs as PI3Kα inhibitors through the fragment-growing strategy. By varying groups at the 3,5-positions of azaindole, we developed the SAR (Structure-activity relationship) and identified a series of potent PI3Kα inhibitors. Representative azaindole derivatives showed activity in a cellular proliferation and apoptosis assays. Moreover, B3 exhibited strong antiangiogenic effects on cancer cells.
- Hong, Seunghee,Lee, Soyoung,Kim, Bomi,Lee, Hyunseung,Hong, Soon-Sun,Hong, Sungwoo
-
supporting information; experimental part
p. 7212 - 7215
(2011/01/03)
-
- PYRROLO-PYRIDINE KINASE MODULATORS
-
The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.
- -
-
Page/Page column 77-78
(2008/12/04)
-
- FUSED RING HETEROCYCLE KINASE MODULATORS
-
The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.
- -
-
Page/Page column 141-142
(2008/12/04)
-
- Pyrrolo-pyridine kinase modulators
-
The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.
- -
-
Page/Page column 61-62
(2010/02/15)
-